NuCana to Present Pancreatic Cancer Data at ESMO
Ticker: NCNA · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, oncology, presentation
TL;DR
NuCana presenting pancreatic cancer drug data at ESMO Sept 3rd.
AI Summary
On September 3, 2025, NuCana plc announced it will present at the European Society for Medical Oncology (ESMO) Congress 2025. The presentation will feature data from the Phase 2 PRODIGE study of NUC-3373 in combination with chemotherapy for advanced pancreatic cancer.
Why It Matters
This presentation could highlight the potential efficacy of NuCana's drug candidate, NUC-3373, in treating a difficult-to-treat cancer, potentially impacting future treatment options.
Risk Assessment
Risk Level: medium — The filing is an announcement of a presentation, which carries inherent risks related to the data that will be presented and its reception by the medical community.
Key Players & Entities
- NuCana plc (company) — Registrant
- NUC-3373 (drug) — Drug candidate
- European Society for Medical Oncology (ESMO) Congress 2025 (event) — Presentation venue
- September 3, 2025 (date) — Announcement date
FAQ
What specific data will NuCana present at the ESMO Congress 2025?
The filing states the presentation will feature data from the Phase 2 PRODIGE study of NUC-3373 in combination with chemotherapy for advanced pancreatic cancer.
What is the drug candidate being discussed?
The drug candidate is NUC-3373.
What type of cancer is the study focused on?
The study is focused on advanced pancreatic cancer.
When was this announcement made?
The announcement was made on September 3, 2025.
What is the name of the study mentioned?
The name of the study is the Phase 2 PRODIGE study.
Filing Stats: 337 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2025-09-03 08:41:23
Filing Documents
- d78987d6k.htm (6-K) — 10KB
- d78987dex991.htm (EX-99.1) — 9KB
- 0001193125-25-194556.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Ian Webster Name: Ian Webster Title: Interim Chief Financial Officer (Principal Financial and Accounting Officer) Date: September 3, 2025